Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.55 USD | -1.50% | -4.90% | +65.20% |
15/05 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
13/05 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.20% | 1.43B | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-1.05% | 21.97B | |
-5.20% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc., Q4 2018 Earnings Call, Mar 07, 2019